PRL-8-53 — Safety, Research, Risks & Legal Status

Not medical advice. PRL-8-53 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride; Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride
Category	Research Chemical
CAS Number	51352-87-5
Molecular Formula	C18H22ClNO2
Developer	Dr. Nikolaus Hansl, Creighton University (1972-1978)
Drug Class	Substituted phenethylamine; experimental hypermnesic agent
Human Trials	One double-blind RCT (1978, n=47); no replications
Animal LD50 (oral, mouse)	Approximately 860 mg/kg
US legal status	Not FDA-approved. Not scheduled under the US Controlled Substances Act and not listed as a controlled analog in most US jurisdictions as of 2025, but regulatory status can change. Sold commercially only as a research chemical labeled "not for human consumption." No ATC code assigned. No clinical trials registered on ClinicalTrials.gov. Individuals purchasing or possessing this compound for personal use do so outside any established regulatory framework.

What is PRL-8-53?

PRL-8-53 is a synthetic substituted phenethylamine developed by Dr. Nikolaus Hansl at Creighton University between 1972 and 1978. It was investigated as a hypermnesic (memory-enhancing) agent. Development was discontinued in the 1980s following Hansl's retirement and a 1985 dispute between Hansl and Creighton University over laboratory access. No pharmaceutical company has pursued further development. The entire published human evidence base consists of a single 1978 double-blind randomized controlled trial.

How it works

Incompletely characterized. Preclinical and limited human data suggest possible cholinergic modulation (acetylcholine system), potentiation of dopaminergic activity, and partial serotonin inhibition. Animal studies indicate it reverses certain reserpine-induced effects. It does not appear to function as a classical stimulant and did not affect motor performance or reaction time in the single human trial. The precise receptor targets and pharmacodynamic mechanism remain unknown.

Background & history

Synthesized by Dr. Nikolaus Hansl (Creighton University, Nebraska) between 1972 and 1978 as part of a program to identify memory-enhancing agents. A single double-blind RCT was published in 1978 in Psychopharmacology (Hansl & Mead, PMID 418433). Development stalled after Hansl's retirement and a 1985 legal dispute with Creighton University over access to experimental materials. The compound attracted no pharmaceutical industry interest and has never been commercialized or advanced to Phase I or beyond.

What the research says

The entirety of controlled human evidence is one double-blind RCT (Hansl & Mead, 1978, n=47 college students aged 18-22). Participants receiving a low oral dose showed approximately 89% improvement in 24-hour verbal retention compared to placebo (10.4 versus 5.5 words recalled; p less than 0.01 to p less than 0.001). No motor impairment or reaction-time changes were observed. No adverse effects were reported at the administered dose. Preclinical (mouse) data show an oral LD50 of approximately 860 mg/kg, suggesting low acute toxicity in that species, along with spasmolytic activity and absence of stimulant properties. No mechanistic studies beyond preliminary characterization exist. No replication trials, dose-ranging studies, long-term safety data, or independent human studies have been conducted. The entire evidence base should be considered extremely limited - one small, single-site, nearly 50-year-old study.

Reported effects

Verbal memory retention improvement in a single small 1978 RCT (effect size approximately 89% over placebo at 24 hours)
No observed motor impairment or reaction-time changes in human trial
Reversal of reserpine-induced effects in animal models (preclinical only)
Spasmolytic activity reported in animal studies (preclinical only)
No stimulant properties observed in preclinical or human data
All effects outside the 1978 RCT are animal-only or unconfirmed

Dosing & administration (informational)

The single 1978 human trial used low oral doses but the exact dose is not publicly specified in most secondary sources; the Hansl & Mead publication (PMID 418433) is the primary reference. These details are reported for informational and literature-reference purposes only and do not constitute a dosing protocol. No safe or effective human dose has been established through replicated clinical research. Anyone considering use should consult a licensed clinician.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Comprehensive human safety profile is essentially unknown due to a single 1978 trial with no long-term follow-up
No serious adverse effects were reported in the single human trial at the dose administered
Animal oral LD50 approximately 860 mg/kg in mice, suggesting low acute toxicity in that species; human extrapolation is unreliable
No carcinogenicity, reproductive toxicity, or chronic toxicity data in humans or animals
No drug interaction studies have been conducted
Sold as a research chemical not for human consumption; self-administration carries unknown risks
Regulatory status may vary by jurisdiction and is subject to change

Drug & supplement interactions

N
o
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
f
o
r
P
R
L
-
8
-
5
3
.
B
a
s
e
d
o
n
t
h
e
p
r
o
p
o
s
e
d
(
u
n
c
o
n
f
i
r
m
e
d
)
m
e
c
h
a
n
i
s
m
s
i
n
v
o
l
v
i
n
g
c
h
o
l
i
n
e
r
g
i
c
,
d
o
p
a
m
i
n
e
r
g
i
c
,
a
n
d
s
e
r
o
t
o
n
e
r
g
i
c
a
c
t
i
v
i
t
y
,
t
h
e
o
r
e
t
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
c
h
o
l
i
n
e
s
t
e
r
a
s
e
i
n
h
i
b
i
t
o
r
s
,
d
o
p
a
m
i
n
e
r
g
i
c
a
g
e
n
t
s
,
s
e
r
o
t
o
n
e
r
g
i
c
d
r
u
g
s
,
a
n
d
a
n
t
i
p
s
y
c
h
o
t
i
c
s
a
r
e
p
l
a
u
s
i
b
l
e
,
b
u
t
n
o
e
m
p
i
r
i
c
a
l
d
a
t
a
s
u
p
p
o
r
t
o
r
q
u
a
n
t
i
f
y
a
n
y
s
p
e
c
i
f
i
c
i
n
t
e
r
a
c
t
i
o
n
.

Who should avoid it

Combining with serotonergic drugs (theoretical interaction risk, no data)
Combining with dopaminergic agents (theoretical interaction risk, no data)
Combining with cholinesterase inhibitors (theoretical additive or adverse cholinergic effects)
Use in pregnancy or lactation (no safety data whatsoever)
Use in individuals with cardiovascular, hepatic, or renal conditions (no safety data)
Purchase from vendors unable to provide third-party purity certification

How it is commonly combined

No evidence base exists for combination use. PRL-8-53 has never been studied in combination with any other compound in humans. Combination ("stacking") is entirely speculative and carries compounded unknown risks. No responsible guidance can be offered.

Legal & regulatory. Not FDA-approved. Not scheduled under the US Controlled Substances Act and not listed as a controlled analog in most US jurisdictions as of 2025, but regulatory status can change. Sold commercially only as a research chemical labeled "not for human consumption." No ATC code assigned. No clinical trials registered on ClinicalTrials.gov. Individuals purchasing or possessing this compound for personal use do so outside any established regulatory framework.

Quality & harm reduction

P
u
r
c
h
a
s
e
d
a
s
a
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
f
r
o
m
u
n
r
e
g
u
l
a
t
e
d
v
e
n
d
o
r
s
.
N
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
s
u
p
p
l
y
e
x
i
s
t
s
.
I
n
d
e
p
e
n
d
e
n
t
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
o
A
)
f
r
o
m
v
e
n
d
o
r
s
s
h
o
u
l
d
b
e
r
e
q
u
e
s
t
e
d
;
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
v
e
r
i
f
i
c
a
t
i
o
n
v
i
a
H
P
L
C
o
r
N
M
R
i
s
a
d
v
i
s
a
b
l
e
b
e
f
o
r
e
a
n
y
r
e
s
e
a
r
c
h
u
s
e
.
A
d
u
l
t
e
r
a
t
i
o
n
r
i
s
k
i
s
p
r
e
s
e
n
t
w
i
t
h
a
n
y
u
n
r
e
g
u
l
a
t
e
d
c
h
e
m
i
c
a
l
s
u
p
p
l
y
c
h
a
i
n
.
C
A
S
5
1
3
5
2
-
8
7
-
5
i
s
l
i
s
t
e
d
o
n
P
u
b
C
h
e
m
(
C
I
D
7
0
7
0
0
8
6
8
)
a
n
d
C
a
y
m
a
n
C
h
e
m
i
c
a
l
f
o
r
r
e
f
e
r
e
n
c
e
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find PRL-8-53 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is there solid human evidence that PRL-8-53 enhances memory?

Evidence is extremely limited. A single 1978 double-blind RCT (n=47) reported approximately 89% improvement in 24-hour verbal retention. That study has never been independently replicated and was conducted nearly 50 years ago by the compound's developer. No modern trials exist.

What is the legal status of PRL-8-53 in the United States?

As of 2025 it is not scheduled under the federal Controlled Substances Act and is not a listed controlled analog in most US jurisdictions. It is sold as a research chemical not for human consumption. State laws vary, and regulatory status can change without notice.

What dose is safe or effective?

No established safe or effective human dose exists. The single published trial used low oral doses but did not publicly specify the exact amount used. Consult a licensed clinician before considering any use; this site does not provide dosing protocols.

Why was development abandoned?

Development stalled after Dr. Hansl's retirement and a 1985 legal dispute between Hansl and Creighton University over access to experimental materials. No pharmaceutical company chose to pursue further development, and no active investigational new drug (IND) application has been filed.

Are there long-term safety data?

No. The safety profile beyond a single short-term human trial is unknown. There are no chronic toxicity, carcinogenicity, reproductive toxicity, or drug interaction studies in humans. Animal data show a high oral LD50 in mice but this does not reliably predict human safety.

Is PRL-8-53 a stimulant?

Based on available preclinical and the single human trial, it does not appear to function as a classical stimulant. The 1978 human trial reported no motor impairment, reaction-time changes, or stimulant-like effects at the dose studied. However, comprehensive pharmacological characterization has never been completed.

References & further reading

PubMed PMID 418433: Hansl NR, Mead BT (1978) - search 'PRL-8-53 enhanced learning retention humans Hansl Mead Psychopharmacology'
Springer Psychopharmacology (1978) 56:249-253 - search 'PRL-8-53 psychotropic agent memory Hansl'
PubChem CID 70700868 - search 'PRL-8-53 methyl benzoate phenethylamine CAS 51352-87-5'
ClinicalTrials.gov - search 'PRL-8-53' (no registered trials identified as of 2025)
Cayman Chemical product 26208 - PRL-8-53 hydrochloride reference standard documentation